Lord, Abbett & Co. LLC Alnylam Pharmaceuticals, Inc. Transaction History

Lord, Abbett & Co. LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Oct 07, 2024	BUY	$185.53 - $241.31 $97.2 Million - $126 Million	523,972 New	523,972 $125 Million
Q4 2022 Feb 10, 2023	BUY	$185.53 - $241.31 $897,965 - $1.17 Million	4,840 Added 0.93%	523,972 $125 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $71.9 Million - $120 Million	519,132 New	519,132 $104 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $5.34 Million - $7.3 Million	-42,000 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$159.56 - $209.29 $38 Million - $49.8 Million	-238,000 Reduced 85.0%	42,000 $7.12 Million
Q3 2021 Nov 09, 2021	BUY	$169.75 - $207.73 $47.5 Million - $58.2 Million	280,000 New	280,000 $52.9 Million
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $26.2 Million - $32 Million	-297,210 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $4.68 Million - $6 Million	40,408 Added 15.74%	297,210 $35.4 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $16.1 Million - $19.7 Million	141,050 Added 121.86%	256,802 $32.6 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $8.4 Million - $13.7 Million	115,752	115,752 $13.6 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.